Blackstone raises three-quarters of targeted $4.6 billion life sciences fund
FILE PHOTO: The ticker and trading information for Blackstone Group is displayed at the post where it is traded on the floor of the New York Stock Exchange (NYSE) April…
Explainer: Making a new generation of ‘guided-missile’ cancer drugs work
FRANKFURT (Reuters) – A class of treatments known as antibody-drug conjugates (ADC) combine cancer-tracking proteins with powerful cell toxins. The therapies are getting a fresh start as dozens of drugmakers…
Drug developers take fresh aim at ‘guided-missile’ cancer drugs
FRANKFURT/ZURICH (Reuters) – Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an…
Novartis, Merck and Allergan join those raising U.S. drug prices for 2020
NEW YORK (Reuters) – Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the…
Bristol-Myers wins $752 million in U.S. patent case against Gilead
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau (Reuters) –…
Biogen scraps development of therapy for rare brain disease
(Reuters) – Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest…
CVS to increase genetic testing for some cancer patients
(This December 12 story corrects to Missouri from Montana in last paragraph) By Caroline Humer and Julie Steenhuysen NEW YORK (Reuters) – CVS Health Corp said on Thursday it will…
Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug
(Reuters) – Shares of Sarepta Therapeutics Inc (SRPT.O) soared 36% on Friday after U.S. regulators shocked Wall Street by approving the company’s treatment for a muscle-wasting disorder less than four…
U.S. FDA gives early approval to Sarepta’s newest DMD treatment
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. REUTERS/Jason Reed/File Photo (Reuters) – The U.S. Food and…
Half of lymphoma patients alive three years after Gilead cell therapy treatment: study
(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to…